ImmVirx
PrivateLast Round
Series B
Jun 5, 2023
Est. Valuation
$49.74M
Total Funding Raised
$48.34M
Company Overview
ImmVirx is a clinical-stage biotechnology company that develops novel oncolytic RNA immunotherapies to treat various types of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmVirx Comparables
Compare ImmVirx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| KaliVir Immunotherapeutics | 84% | |
| TILT Biotherapeutics | 83% | |
| ImmVira | 82% | |
ImmVirx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 5, 2023 | ||||
| Series A | Nov 8, 2021 | ||||
| Series A | May 14, 2021 | ||||
| Seed | Jan 1, 2020 |
Key People
Founding team and executive leadership
ImmVirx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OneVentures | Series B |
| Acorn Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 8, 2021
Raised $18.5M led by Acorn Capital
ImmVirx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImmVirx's valuation, stock price, and market status.